依达拉奉注射液治疗颅脑外伤脑梗死的临床研究

发布时间：2018-03-21 02:04

本文选题：依达拉奉　切入点：颅脑外伤　出处：《中国临床药理学杂志》2017年13期 　论文类型：期刊论文

【摘要】：目的探究依达拉奉治疗外伤性脑梗死的临床疗效和安全性。方法 72例颅脑外伤性脑梗死患者随机分为对照组36例和试验组36例。对照组患者给予降颅压、神经营养及改善微循环等常规治疗,试验组患者在此基础上予以静脉滴注依达拉奉注射液20 mL+0.9%NaCl 200 m L,bid,共14天。治疗后,对比2组患者的血液流变学变化情况,并依据格拉斯哥评分情况对2组患者的预后恢复情况进行评价,同时对临床用药安全性进行评价比较。结果试验组和对照组的总有效率分别为91.67%(33/36例)和72.22%(26/36例),差异均有统计学意义(均P0.05)。治疗14天后,试验组和对照组的高切全血黏度分别为(4.73±0.56),(5.36±0.78)m Pa·s;低切全血粘度分别为(8.15±1.03),(9.54±1.26)mPa·s;血浆黏度分别为(1.41±0.15),(1.76±0.19)mPa·s;红细胞压积分别为(37.15±3.21)%,(43.17±4.03)%;纤维蛋白为分别为(3.58±0.45),(4.67±0.54)g·L~(-1),差异均有统计学意义(均P0.05)。试验组的药物不良反应发生率为5.56%(1/36例),对照组为2.78%(2/36例),差异无统计学意义(P0.05)。结论依达拉奉能够显著改善颅脑外伤脑梗死患者的血液流变学指标,其治疗效果优于常规神经外科治疗,对颅脑外伤脑梗死的临床治疗起到积极作用。
[Abstract]:Objective to investigate the clinical efficacy and safety of Edaravone in the treatment of traumatic cerebral infarction. Methods 72 patients with traumatic cerebral infarction were randomly divided into control group (n = 36) and experimental group (n = 36). The patients in the experimental group were treated with 20 mL Edaravone 20 mL 0.9 mL NaCl 200 mL bid for 14 days. After treatment, the changes of hemorheology in the two groups were compared. According to the Glasgow score, the prognosis of the two groups was evaluated. Results the total effective rates of the trial group and the control group were 91.67 / 36 and 72.2222 / 26 / 36, respectively. The difference was statistically significant (all P0.055.After 14 days of treatment, the total effective rates of the trial group and the control group were 91.67 / 36) and 72.22 / 26 / 36 respectively (P < 0.05). The high shear whole blood viscosity of the test group and the control group was 4.73 卤0.56 卤0.78 MPA 路s, the low shear whole blood viscosity was 8.15 卤1.03 卤1.26 mPa 路s, the plasma viscosity was 1.41 卤0.151.76 卤0.19 MPA 路s, the hematocrit was 37.15 卤3.21mPa 路s, the fibrin was 3.58 卤0.454.67 卤0.54 g 路L ~ (-1), the difference was statistically significant (P < 0.05). The incidence of adverse drug reactions was 5.56 / 1 / 36 in the control group and 2.78 / 2 / 36 in the control group (P < 0.05). Conclusion Edaravone can significantly improve the hemorheological parameters of patients with cerebral infarction after craniocerebral injury. The therapeutic effect is better than that of conventional neurosurgery, and it plays a positive role in the clinical treatment of cerebral infarction after craniocerebral trauma.
【作者单位】：兰州大学第二医院神经外科;
【基金】：甘肃省自然科学基金资助项目(1506RJZA222)
【分类号】：R651.15;R743.33

【参考文献】